Adherium Opens Retail Entitlement Offer to Raise Capital

The latest update is out from Adherium Ltd. ( (AU:ADR) ).

Adherium Limited has opened the retail component of its accelerated non-renounceable entitlement offer, aiming to raise up to approximately $816,377 from eligible shareholders. The company has dispatched the Retail Offer Booklet and personalised entitlement and acceptance forms to eligible retail investors, with applications closing at 5.00 pm AEDT on 5 March 2026 and new shares expected to be allotted on 12 March and commence normal trading on 13 March, underscoring an incremental capital-raising step to support its ongoing operations and market activities.

The timetable confirms a swift execution window for retail investors, aligning the capital raising with broader efforts previously outlined in earlier announcements this month. While specific use of proceeds is not detailed in this notice, the offer structure and accelerated schedule indicate a focus on reinforcing the company’s balance sheet and maintaining momentum in its digital respiratory health strategy, which may help sustain its positioning in a competitive medtech and digital health market.

The most recent analyst rating on (AU:ADR) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Adherium Ltd. stock, see the AU:ADR Stock Forecast page.

More about Adherium Ltd.

Adherium Limited is an Australia-based medical technology company focused on digital health solutions for respiratory conditions. It develops and supplies connected inhaler devices and adherence monitoring platforms that support patients, clinicians and payers in managing chronic respiratory diseases, with its products marketed under brands such as Hailie.

Technical Sentiment Signal: Sell

Current Market Cap: A$21.64M

See more data about ADR stock on TipRanks’ Stock Analysis page.